CINECA IRIS Institutional Research Information System

BOCCI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.688
AS - Asia 9.901
EU - Europa 7.488
SA - Sud America 1.347
AF - Africa 435
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 43.890
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.087
SG - Singapore 3.052
CN - Cina 2.711
IT - Italia 2.467
HK - Hong Kong 1.651
BR - Brasile 1.096
SE - Svezia 1.086
VN - Vietnam 897
DE - Germania 891
BG - Bulgaria 640
CA - Canada 463
GB - Regno Unito 446
TR - Turchia 444
FR - Francia 443
FI - Finlandia 371
RU - Federazione Russa 300
UA - Ucraina 260
IN - India 241
JP - Giappone 208
CI - Costa d'Avorio 161
KR - Corea 139
BD - Bangladesh 112
AT - Austria 108
CH - Svizzera 100
AR - Argentina 79
MX - Messico 68
NL - Olanda 65
IQ - Iraq 59
BE - Belgio 55
PL - Polonia 55
SA - Arabia Saudita 50
NG - Nigeria 46
ZA - Sudafrica 43
PK - Pakistan 42
GR - Grecia 40
ID - Indonesia 40
CO - Colombia 36
ES - Italia 36
MA - Marocco 36
SN - Senegal 36
EC - Ecuador 33
UZ - Uzbekistan 33
VE - Venezuela 31
PY - Paraguay 23
KE - Kenya 22
AU - Australia 21
PH - Filippine 20
EG - Egitto 18
TN - Tunisia 18
CZ - Repubblica Ceca 17
JO - Giordania 17
IE - Irlanda 16
IL - Israele 16
LT - Lituania 16
CL - Cile 15
IR - Iran 15
UY - Uruguay 15
AE - Emirati Arabi Uniti 14
MY - Malesia 14
NP - Nepal 14
PS - Palestinian Territory 14
TT - Trinidad e Tobago 14
PE - Perù 13
RO - Romania 13
DK - Danimarca 12
BJ - Benin 11
DZ - Algeria 11
OM - Oman 11
AZ - Azerbaigian 10
JM - Giamaica 10
HU - Ungheria 9
LB - Libano 9
CR - Costa Rica 8
HR - Croazia 8
KZ - Kazakistan 8
BB - Barbados 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
KW - Kuwait 7
TH - Thailandia 7
AL - Albania 6
AM - Armenia 6
KH - Cambogia 6
NI - Nicaragua 6
PT - Portogallo 6
TW - Taiwan 6
BO - Bolivia 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
RS - Serbia 5
BW - Botswana 4
GE - Georgia 4
KG - Kirghizistan 4
SY - Repubblica araba siriana 4
BH - Bahrain 3
GA - Gabon 3
HN - Honduras 3
LK - Sri Lanka 3
MK - Macedonia 3
AG - Antigua e Barbuda 2
Totale 43.833
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.821
Ashburn 2.377
Ann Arbor 1.960
Houston 1.904
Fairfield 1.826
Singapore 1.743
Hong Kong 1.624
San Jose 1.191
Dallas 1.184
Chandler 1.176
Santa Clara 1.062
Seattle 865
Wilmington 713
Cambridge 687
Sofia 638
Shanghai 605
Milan 574
Beijing 560
Serra 480
New York 465
Boardman 361
Ottawa 350
Los Angeles 329
Jacksonville 298
Princeton 274
Izmir 272
Lawrence 257
Lauterbourg 233
Council Bluffs 232
Medford 220
Nanjing 200
Ho Chi Minh City 199
Tokyo 182
Des Moines 164
Abidjan 161
Dong Ket 159
Hefei 155
Hanoi 154
Dearborn 153
Munich 136
Istanbul 127
Seoul 125
London 105
Redondo Beach 103
Frankfurt am Main 102
Pisa 99
Rome 98
Buffalo 96
Florence 94
Columbus 93
The Dalles 92
Nanchang 91
San Diego 91
São Paulo 86
Vienna 86
Helsinki 84
Falls Church 83
Bern 80
Washington 80
Boulder 75
Ogden 68
Turku 68
Redwood City 58
Düsseldorf 57
Brussels 52
Jüchen 51
Bremen 50
Lagos 45
Warsaw 45
Kunming 44
Rio de Janeiro 42
Hebei 40
Orem 39
Shenyang 39
Phoenix 38
Changsha 37
Belo Horizonte 36
Dakar 36
Lucca 36
Fuzhou 35
Norwalk 35
Pune 35
Marseille 34
Da Nang 32
Denver 32
Guangzhou 32
Rho 31
Nuremberg 30
Tashkent 30
Montreal 29
Nürnberg 29
Atlanta 28
Jiaxing 28
Seacroft 28
Tianjin 28
Haiphong 27
Toronto 27
Baltimore 26
San Francisco 26
Chicago 24
Totale 32.341
Salva come PNG Salva come JPEG
Nome #
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 547
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 416
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 374
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 354
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 302
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 284
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma 273
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 267
John Hunter and the origin of the term “angiogenesis”. 264
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 256
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 255
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 254
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 252
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 251
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 248
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 244
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 244
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 243
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 242
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 237
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 234
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 231
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 227
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. 216
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 214
Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? 212
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 209
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 208
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 208
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 205
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity 204
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 202
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 201
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies 198
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 198
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients 198
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 197
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 197
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation 196
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 196
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients 195
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 193
Chronic administration of suramin induces neurotoxicity in rats 192
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization 190
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine 190
Tumor Dormancy, Angiogenesis and Metronomic Chemotherapy 188
Appropriateness of repetitive therapeutic drug monitoring and laboratory turn around time 188
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents 187
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 187
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 186
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 185
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy 185
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice 185
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 185
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 184
Scholars and scientists in the history of the lymphatic system 184
Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis 183
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 183
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: synthesis and pharmacological effects 182
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 182
The pharmacological bases of the antiangiogenic activity of paclitaxel 181
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 181
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 178
Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate 178
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 177
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. 175
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer 175
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 174
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 172
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules 171
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 171
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 170
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines 169
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 169
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 169
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 168
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 167
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation 167
Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? 165
Derivati a nucleo benzo[d]isotiazol-3(2H)-one-1,1-diossido e loro impiego nel trattamento di tumori 165
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients 165
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 164
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 164
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 164
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 163
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 163
Endometriosis Index: A software-derived score to predict the presence and severity of the disease 162
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer 162
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling 162
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 161
Pharmacogenetics of Antiangiogenic Therapy 161
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections 161
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice 160
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 159
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors? 158
Totale 20.484
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.884 50 209 79 132 494 489 91 128 128 115 158 811
2022/20233.577 463 445 254 331 447 458 13 269 636 21 196 44
2023/20242.569 302 289 318 171 350 466 77 108 65 47 104 272
2024/20258.284 45 335 80 452 746 864 649 448 860 1.119 863 1.823
2025/202610.419 659 1.208 1.253 834 986 841 1.487 521 674 918 723 315
2026/202760 60 0 0 0 0 0 0 0 0 0 0 0
Totale 44.531